Biotest

What Biotest does

Biotest GmbH & Co. KGaA is a German plasma-derived biopharmaceutical company founded in 1946 and headquartered in Dreieich, Germany. It develops, manufactures, and commercializes therapeutics across three core therapy areas: hematology (bleeding disorders such as hemophilia A and B, via Haemoctin SDH and Haemonine), clinical immunology (primary immunodeficiencies, immune thrombocytopenia, and hyperimmune conditions, via Yimmugo, Intratect, Cytotect CP, Hepatect CP, Varitect CP, and Zutectra), and intensive care medicine (severe infections, coagulation disorders, and volume/protein substitution, via Albiomin, Biseko, Cofact, Pentaglobin, and Prufibry). The company's underlying technology is plasma fractionation and purification from human plasma, with proprietary production processes yielding differentiated compositions such as IgM-enriched Pentaglobin and the novel IgM/IgA/IgG Trimodulin (BT588). An industrial human serum albumin product is also sold to biopharmaceutical manufacturers as a GMP-grade excipient.

Biotest's pipeline is anchored by Trimodulin (Phase III ESsCAPE study for severe community-acquired pneumonia), Yimmugo / IgG Next Generation (BT595, approved in Germany, Austria, and UK with further approvals ongoing), and Fibrinogen / Prufibry / Fesilty (BT524, approved and launched). The Biotest Next Level manufacturing facility is under development to scale Yimmugo production. Since 2017, Biotest has been majority-owned by Spanish plasma major Grifols, which provides plasma sourcing, distribution leverage, and capital backing, while Biotest retains its own listed-company governance (Frankfurt Stock Exchange ticker BIO; legal form changed from AG to GmbH & Co. KGaA in 2023). The company distributes prescription-based plasma products directly to hospitals, specialty clinics, and intensive care units through dedicated ordering systems in Germany and via international channels, with US commercialization of Yimmugo licensed to Kedrion Biopharma under a partnership announced in October 2025 following FDA approval in 2024. Biotest's revenue is not disclosed in the source data; the company employs 1,001–5,000 people across operations in Germany, Austria, Switzerland, and Hungary, with its website currently restricted to German users.

Name

Biotest

Legal name

Biotest GmbH & Co. KGaA

Website

https://biotest.com

Company type

Public

Founded year

1946

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Biotest GmbH & Co. KGaA is a German plasma-derived biopharmaceutical company developing and manufacturing therapeutics for hematology, clinical immunology, and intensive care medicine, serving hospitals and specialty clinics across Europe and, via licensing partner Kedrion, the US.

Ownership category

akta.pro rank

Product category

Plasma-derived biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

akta.pro secondary industries

Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Hyperimmune (Specific) Immunoglobulins (e.g., Anti-D, Tetanus, Rabies, Hep B) (HLAIAHAE), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL), Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)

Keywords

• Plasma-derived therapeutics
• Immunoglobulin therapies
• Coagulation factor concentrates
• Human serum albumin
• Haematology pharmaceuticals

Headquarters

HQ city

Dreieich

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Plasma-derived pharmaceuticals: Sale of plasma-derived therapeutic products including immunoglobulins for clinical immunology, albumin and other proteins for intensive care medicine, and coagulation factors for hematology. Products are sold to hospitals, clinics, and healthcare institutions through direct prescription-based channels.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Biotest develops, manufactures, and sells plasma-derived therapeutic proteins for haematology, clinical immunology, and intensive care medicine. Its product range includes immunoglobulins (polyvalent and hyperimmune), coagulation factor concentrates for haemophilia and fibrinogen deficiency, human albumin and plasma protein solutions for critical care, and an industrial GMP-grade human serum albumin for biopharmaceutical excipient use. Products are sold as prescription pharmaceuticals to hospitals, specialty clinics, intensive care units, and biopharmaceutical manufacturers, primarily through direct institutional sales.

Product overview

Biotest is a plasma-derived biopharmaceutical company offering a diversified portfolio of products across three therapeutic areas: Haematology (Haemoctin® SDH, Haemonine® for Haemophilia A and B treatment), Clinical Immunology (Yimmugo®, Cytotect® CP, Hepatect® CP, Varitect® CP, Intratect®, Zutectra® for antibody deficiencies and viral infections), and Intensive Care Medicine (Albiomin®, Biseko®, Cofact®, Pentaglobin®, Prufibry® for volume replacement, coagulation disorders, and severe infections). The company also supplies Biotest Human Serum Albumin for industrial/biotech applications. The pipeline includes Trimodulin (BT588) for severe community-acquired pneumonia, IgG Next Generation/Yimmugo (BT595) for PID and ITP, and Fibrinogen/Prufibry/Fesilty (BT524) for fibrinogen deficiency, all in various clinical development phases.

Differentiator

Problem solved

Functional benefit

Brands

• Biotest Next Level: New manufacturing facility under development for production of IgG Next Generation / Yimmugo products.

Products and services

• Haemoctin SDH

Quantifiable outcome

• Trimodulin may prevent progression of severe community-acquired pneumonia, including the need for invasive mechanical ventilation and other intensive care procedures
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Kedrion BiopharmamajorChannel Partner/ Reseller/ Distributor · 9 October 2025Licensing and commercialization agreement for Yimmugo immunoglobulin therapy. Kedrion Biopharma commercialized Yimmugo in the US market under FDA approval obtained in 2024. The product is an innovation in immunoglobulin treatment catering to over 500,000 people in the US affected by primary immunodeficiency.

Scale indicators2 records

Recent moves7 records

Expansion highlights6 records

Regional players

• China Biologic Products Holdings: Chinese plasma-derived therapeutics producer manufacturing albumin, immunoglobulins, and coagulation factors. Regional peer with comparable plasma fractionation business model primarily serving the Chinese market.
• Sanquin Plasma Products: Dutch blood supply foundation with a plasma products division manufacturing immunoglobulins, coagulation factors, and albumin. Comparable plasma fractionation business primarily serving the Netherlands and selected European markets.
• Bio Products Laboratory (BPL): UK-based plasma fractionator producing immunoglobulins (Gammaplex, Vigam), albumin, and coagulation factors. Comparable mid-sized plasma therapeutics player with focus on UK and selected international markets.

Direct peers

• Octapharma: Swiss-headquartered global plasma fractionator offering immunoglobulins (Octagam, Octanate), coagulation factors, and albumin. Direct competitor in plasma-derived therapeutics with comparable mid-sized scale and European manufacturing footprint.
• Takeda Pharmaceutical Company (Plasma-Derived Therapies): Takeda's Plasma-Derived Therapies division (formerly Shire/Baxalta) markets immunoglobulins (Gammagard, Hyqvia) and albumin globally. Direct competitor in IVIG and specialty plasma products with broader therapeutic area reach and larger commercial infrastructure.
• Kedrion Biopharma: Italian plasma-derived therapeutics company producing immunoglobulins, coagulation factors, and albumin. Direct peer in plasma fractionation and current US distribution partner for Biotest's Yimmugo, making it both a competitor and partner in specific markets.
• CSL Behring: CSL Behring is the global leader in plasma-derived therapeutics, producing immunoglobulins (Privigen, Hizentra), albumin, and coagulation factors. Directly competes with Biotest across all three therapy areas (hematology, immunology, intensive care) with significantly larger scale and broader geographic reach.
• LFB (Laboratoire français du Fractionnement et des Biotechnologies): French state-linked plasma fractionator producing immunoglobulins (Tegeline, Clairyg), coagulation factors, and albumin. Direct competitor in plasma-derived therapeutics with similar European focus and comparable mid-market positioning.

Emerging players

• ADMA Biologics: US-focused plasma-derived immunoglobulin company marketing ASCENIV, BIVIGAM, and Nabi-HB for primary immunodeficiency and hepatitis B. Smaller-scale emerging competitor with similar focus on specialty plasma-derived immunoglobulins and hyperimmune products.

Broad incumbents

• Grifols: Spanish plasma therapeutics giant and Biotest's majority shareholder. Competes across the same plasma product categories (immunoglobulins, albumin, coagulation factors, hyperimmunes) at substantially larger global scale with the world's largest plasma collection network.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biotest-group
• Instagraminstagram.com/biotest_group
• Xx.com/biotestag

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotest